NYSE - Nasdaq Real Time Price • USD
Becton, Dickinson and Company (BDX)
At close: April 22 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 13 | 12 | 14 | 14 |
Avg. Estimate | 2.97 | 3.43 | 12.95 | 14.35 |
Low Estimate | 2.92 | 3.37 | 12.9 | 14.06 |
High Estimate | 3.02 | 3.62 | 13.05 | 14.59 |
Year Ago EPS | 2.86 | 2.96 | 12.21 | 12.95 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 12 | 11 | 13 | 14 |
Avg. Estimate | 5.04B | 5.14B | 20.3B | 21.49B |
Low Estimate | 5.01B | 5.11B | 20.2B | 21.36B |
High Estimate | 5.07B | 5.17B | 20.35B | 21.64B |
Year Ago Sales | -- | -- | 19.37B | 20.3B |
Sales Growth (year/est) | -- | -- | 4.80% | 5.90% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 2.74 | 2.91 | 3.43 | 2.4 |
EPS Actual | 2.86 | 2.96 | 3.42 | 2.68 |
Difference | 0.12 | 0.05 | -0.01 | 0.28 |
Surprise % | 4.40% | 1.70% | -0.30% | 11.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 2.97 | 3.43 | 12.95 | 14.35 |
7 Days Ago | 2.97 | 3.43 | 12.95 | 14.35 |
30 Days Ago | 2.96 | 3.43 | 12.94 | 14.34 |
60 Days Ago | 2.96 | 3.43 | 12.94 | 14.34 |
90 Days Ago | 2.99 | 3.47 | 12.84 | 14.26 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 1 | -- | 2 | 2 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
CURRENCY IN USD | BDX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 3.80% | -- | -- | 0.20% |
Next Qtr. | 15.90% | -- | -- | 9.40% |
Current Year | 6.10% | -- | -- | 4.40% |
Next Year | 10.80% | -- | -- | 13.40% |
Next 5 Years (per annum) | 8.65% | -- | -- | 11.07% |
Past 5 Years (per annum) | 1.39% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Barclays: Overweight to Overweight | 2/5/2024 |
Maintains | Raymond James: Outperform to Outperform | 1/3/2024 |
Maintains | Morgan Stanley: Overweight to Overweight | 12/4/2023 |
Maintains | Piper Sandler: Overweight to Overweight | 11/10/2023 |
Maintains | Raymond James: Outperform to Outperform | 11/10/2023 |
Maintains | Citigroup: Neutral to Neutral | 8/21/2023 |
Related Tickers
EMBC Embecta Corp.
10.72
+0.94%
BAX Baxter International Inc.
40.40
+2.36%
RMD ResMed Inc.
180.35
+0.84%
ALC Alcon Inc.
80.61
+1.33%
HOLX Hologic, Inc.
76.22
+1.11%
WST West Pharmaceutical Services, Inc.
375.35
+0.89%
MMSI Merit Medical Systems, Inc.
73.25
+1.69%
COO The Cooper Companies, Inc.
90.04
-0.42%
TFX Teleflex Incorporated
207.27
+0.34%
NVST Envista Holdings Corporation
20.11
+0.75%